GeoVax Labs (GOVX) Interest & Investment Income (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Interest & Investment Income of $15494.0 for Q2 2026, down 68.46% year-over-year from $49123.0 in Q2 2025, and down 33.6% quarter-over-quarter from $23333.0 in Q4 2025.
GeoVax Labs (GOVX) Interest & Investment Income (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Interest & Investment Income for 17 consecutive years, with $15494.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 68.46% year-over-year to $15494.0; the TTM figure through Jun 2026 stood at $142251.0 (down 38.57% YoY), while the FY2025 annual figure was $174276.0, up 0.53% from the prior year.
- Interest & Investment Income slipped to $15494.0 in Q2 2026 per GOVX's latest filing, from $23333.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $251201.0 in Q2 2023 and bottomed at $527.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $67455.6 across 5 years, with a median of $47519.0 in 2025.
- Annual changes were most pronounced in 2023 — Interest & Investment Income surged 44055.22% — and 2024, when it tumbled 97.82%.
- GeoVax Labs' Interest & Investment Income stood at $3692.0 in 2022, then soared by 2644.91% to $101342.0 in 2023, then decreased by 19.33% to $81748.0 in 2024, then tumbled by 71.46% to $23333.0 in 2025, then slumped by 33.6% to $15494.0 in 2026.
- Business Quant data shows GOVX's Interest & Investment Income at $15494.0 in Q2 2026, $23333.0 in Q4 2025, and $54301.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | 15,494.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15,494.00 |
| Dec 31, 2025 | 23,333.00 |
| Sep 30, 2025 | 54,301.00 |
| Jun 30, 2025 | 49,123.00 |
| Mar 31, 2025 | 47,519.00 |
| Dec 31, 2024 | 81,748.00 |
| Sep 30, 2024 | 53,191.00 |
| Jun 30, 2024 | 5,471.00 |
| Mar 31, 2024 | 32,949.00 |
| Dec 31, 2023 | 101,342.00 |
| Sep 30, 2023 | 190,936.00 |
| Jun 30, 2023 | 251,201.00 |
| Mar 31, 2023 | 232,698.00 |
| Dec 31, 2022 | 3,692.00 |
| Sep 30, 2022 | 2,431.00 |
| Jun 30, 2022 | 789.00 |
| Mar 31, 2022 | 527.00 |
| Dec 31, 2021 | 738.00 |
| Sep 30, 2021 | 877.00 |
| Jun 30, 2021 | 1,068.00 |